TRAIL

TRAIL Molekülinformation

Englischer Name	Tumor necrosis factor ligand superfamily member 10	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	1	Target-Alias	CD253，Apo-2 ligand，TNFSF10，TNF Superfamily Member 10，APO2L，Tumor Necrosis Factor Apoptosis-Inducing Ligand Splice Variant Delta，Tumor Necrosis Factor Ligand Superfamily Member 10，Tumor Necrosis Factor (Ligand) Family， Member 10，TNF-Related Apoptosis Inducing Ligand TRAIL，TNF-Related Apoptosis-Inducing Ligand，Tumor Necrosis Factor Ligand 6A，CD253 Antigen，Protein TRAIL，TNLG6A，TL2，TRAIL，Apo-2L，Tumor Necrosis Factor (Ligand) Superfamily， Member 10，Chemokine Tumor Necrosis Factor Ligand Superfamily Member 10，Tumor Necrosis Factor Superfamily Member 10
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

Englischer Name	Tumor necrosis factor ligand superfamily member 10
Target-Alias	CD253，Apo-2 ligand，TNFSF10，TNF Superfamily Member 10，APO2L，Tumor Necrosis Factor Apoptosis-Inducing Ligand Splice Variant Delta，Tumor Necrosis Factor Ligand Superfamily Member 10，Tumor Necrosis Factor (Ligand) Family， Member 10，TNF-Related Apoptosis Inducing Ligand TRAIL，TNF-Related Apoptosis-Inducing Ligand，Tumor Necrosis Factor Ligand 6A，CD253 Antigen，Protein TRAIL，TNLG6A，TL2，TRAIL，Apo-2L，Tumor Necrosis Factor (Ligand) Superfamily， Member 10，Chemokine Tumor Necrosis Factor Ligand Superfamily Member 10，Tumor Necrosis Factor Superfamily Member 10
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	1
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

TRAIL Produktliste

Attribut
Protein (2)
Produktbibliothek
Online (2)
Spezies
Human (2)
Etikett
Fc Tag (1)His Tag (1)
Marker
Unconjugated (2)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
TRL-H5243	Human	HEK293	Human TRAIL / TNFSF10 Protein, His Tag, active trimer (MALS verified)				In den Warenkorb legen
TRL-H5263	Human	HEK293	Human TRAIL / TNFSF10 Protein, Fc Tag, active trimer (MALS verified)				In den Warenkorb legen

Gesamtmenge2

TRAIL Molekülhintergrund

TRAIL, also known as TNFSF10, APO2L, Apo-2L, CD253, TL2, TRAIL, TNLG6A and TNF superfamily member 10. The TRAIL gene as a drug target, induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis. TRAIL also binds the receptors DcR1 and DcR2, which do not contain a cytoplasmic domain (DcR1) or contain a truncated death domain (DcR2). DcR1 functions as a TRAIL-neutralizing decoy-receptor. The cytoplasmic domain of DcR2 is functional and activates NFkappaB. In cells expressing DcR2, TRAIL binding therefore activates NFkappaB, leading to transcription of genes known to antagonize the death signaling pathway and/or to promote inflammation.

TRAIL Molekülalias

Apo-2L,TRAIL,CD253,TNFSF10,Apo-2 ligand

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
AS-1501	AS-1501	Phase 2 Clinical	Shenzhen Zhongke Amshenn Pharmaceutical Co Ltd	Acute-On-Chronic Liver Failure; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liver Injury, Chronic; Hepatic Insufficiency; Hepatitis; Liver Failure; Myocardial Infarction; Reperfusion Injury	Details